Skip to main content

Research Repository

Advanced Search

All Outputs (52)

Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK (2023)
Journal Article
Nakafero, G., Grainge, M. J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., …Abhishek, A. (2023). Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. BMJ, 381, Article e074678. https://doi.org/10.1136/bmj-2022-074678

OBJECTIVE: To develop and validate a prognostic model to inform risk stratified decisions on frequency of monitoring blood tests during long term methotrexate treatment. DESIGN: Retrospective cohort study. SETTING: Electronic health records within th... Read More about Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine, cyclop... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial..

Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study (2023)
Journal Article
Figueroa‐Mora, R., Rampotas, A., Halperin, D., Worth, T., Vidler, J., Melotti, D., …Martinez‐Calle, N. (2023). Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study. British Journal of Haematology, 202(1), 48-53. https://doi.org/10.1111/bjh.18738

This retrospective, observational study evaluated patterns of inpatient versus outpatient tumour lysis syndrome (TLS) monitoring during venetoclax ramp-up in 170 patients with chronic lymphocytic leukaemia. The primary outcome was clinical/biochemica... Read More about Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma (2023)
Journal Article
Van Le, H., Van Naarden Braun, K., Nowakowski, G. S., Sermer, D., Radford, J., Townsend, W., …Hasskarl, J. (2023). Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma. Leukemia & Lymphoma, 64(3), 573-585. https://doi.org/10.1080/10428194.2022.2160200

This study used a real-world population as a synthetic comparator for the single-arm TRANSCEND NHL 001 study (TRANSCEND; NCT02631044) to evaluate the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional (noncellular) therapies i... Read More about Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed/refractory large B-cell lymphoma.

A realist evaluation of a multifactorial falls prevention programme in care homes (2022)
Journal Article
Leighton, P. A., Darby, J., Allen, F., Cook, M., Evley, R., Fox, C., …Logan, P. (2022). A realist evaluation of a multifactorial falls prevention programme in care homes. Age and Ageing, 51(12), Article afac263. https://doi.org/10.1093/ageing/afac263

BACKGROUND: falls in care homes are common, costly and hard to prevent.Multifactorial falls programmes demonstrate clinical and cost-effectiveness, but the heterogeneity of the care home sector is a barrier to their implementation. A fuller appreciat... Read More about A realist evaluation of a multifactorial falls prevention programme in care homes.

Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management (2022)
Journal Article
Tse, E., P. Fox, C. P., Glover, A., Yoon, S. E., Kim, W. S., & Kwong, Y. L. (2022). Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management. Seminars in Hematology, 59(4), 198-209. https://doi.org/10.1053/j.seminhematol.2022.10.002

Natural killer (NK)/T-cell lymphomas arise mainly from NK-cells and occasionally T-cells, and are universally infected with Epstein Barr virus (EBV). They are uncommon lymphomas more prevalent in Asian and Central/South American populations. NK/T-cel... Read More about Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management.

International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. (2022)
Journal Article
Khwaja, J., Kirkwood, A. A., Isbell, L. K., Steffanoni, S., Goradia, H., Pospiech, L., Fail, T., Nicholson, E., Fletcher, K., Linton, K. M., Parsons, K. E., Elmusharaf, N., Eccersley, L., Eyre, T. A., Chaganti, S., Smith, J., Thakrar, N., Kutilina, A., Calimeri, T., Martinez-Calle, N., …Cwynarski, K. (2023). International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphoma. Haematologica, 108(3), 882-888. https://doi.org/10.3324/haematol.2022.281640

Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. (2022)
Journal Article
Wendler, J., Fox, C. P., Valk, E., Steinheber, C., Fricker, H., Isbell, L. K., Neumaier, S., Okosun, J., Scherer, F., Ihorst, G., Cwynarski, K., Schorb, E., & Illerhaus, G. (2022). Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma. BMC Cancer, 22(1), Article 971. https://doi.org/10.1186/s12885-022-09723-w

Background: Primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (PCNSL) is a rare disorder with an increasing incidence over the past decades. High-level evidence has been reported for the MATRix regimen (high-dose methotrexat... Read More about Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma..

Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group (2022)
Journal Article
Steffanoni, S., Calimeri, T., Laurenge, A., Fox, C. P., Soussain, C., Grommes, C., Tisi, M. C., Boot, J., Crosbie, N., Visco, C., Arcaini, L., Chaganti, S., Sassone, M. C., Alencar, A., Armiento, D., Romano, I., Dietrich, J., Itchaki, G., Bruna, R., Fracchiolla, N. S., …Ferreri, A. J. M. (2022). Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. British Journal of Haematology, 199(4), 507-519. https://doi.org/10.1111/bjh.18396

To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study... Read More about Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. (2022)
Journal Article
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., Celico, C., Falautano, M., Nonis, A., La Rosée, P., Binder, M., Fabbri, A., Ilariucci, F., Krampera, M., Roth, A., Hemmaway, C., Johnson, P. W., Linton, K. M., Pukrop, T., Gørløv, J. S., Balzarotti, M., …IELSG32 study investigators. (2022). Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia, 36(7), 1870-1878. https://doi.org/10.1038/s41375-022-01582-5

219 HIV-negative adults ≤70 years with primary CNS lymphoma (PCNSL) were enrolled in the randomized IELSG32 trial. Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or metho... Read More about Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial..

Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. (2022)
Journal Article
Lim, S. H., Stuart, B., Joseph-Pietras, D., Johnson, M., Campbell, N., Kelly, A., Jeffrey, D., Turaj, A. H., Rolfvondenbaumen, K., Galloway, C., Wynn, T., Coleman, A. R., Ward, B., Long, K., Coleman, H., Mundy, C., Bates, A. T., Ayres, D., Lown, R., Falconer, J., …Goldblatt, D. (2022). Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. Nature Cancer, 3(5), 552-564. https://doi.org/10.1038/s43018-022-00364-3

Patients with hematological malignancies are at increased risk of severe COVID-19 outcomes due to compromised immune responses, but the insights of these studies have been compromised due to intrinsic limitations in study design. Here we present the... Read More about Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study..

Rare central nervous system lymphomas (2022)
Journal Article
Kaji, F. A., Martinez‐Calle, N., Sovani, V., & Fox, C. P. (2022). Rare central nervous system lymphomas. British Journal of Haematology, 197(6), 662-678. https://doi.org/10.1111/bjh.18128

Central nervous system (CNS) lymphomas are rare malignancies characterised by lymphoid infiltration into the brain, spinal cord, cranial nerves, meninges and/or eyes in the presence or absence of previous or concurrent systemic disease. Most CNS lymp... Read More about Rare central nervous system lymphomas.

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. (2022)
Journal Article
Wilson, M. R., Eyre, T. A., Kirkwood, A. A., Wong Doo, N., Soussain, C., Choquet, S., Martinez-Calle, N., Preston, G., Ahearne, M., Schorb, E., Moles-Moreau, M.-P., Ku, M., Rusconi, C., Khwaja, J., Narkhede, M., Lewis, K. L., Calimeri, T., Durot, E., Renaud, L., Øvlisen, A. K., …McKay, P. (2022). Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. Blood, 139(16), 2499-2511. https://doi.org/10.1182/blood.2021014506

Prophylactic high-dose methotrexate (HD-MTX) is often used for diffuse large B-cell lymphoma (DLBCL) patients at high risk of central nervous system (CNS) relapse, despite limited evidence demonstrating efficacy or the optimal delivery method. We con... Read More about Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients..

Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline (2021)
Journal Article
Fox, C. P., Ahearne, M. J., Pettengell, R., Dearden, C., El-Sharkawi, D., Kassam, S., …Collins, G. (2022). Guidelines for the management of mature T‐ and natural killer‐cell lymphomas (excluding cutaneous T‐cell lymphoma): a British Society for Haematology Guideline. British Journal of Haematology, 196(3), 507-522. https://doi.org/10.1111/bjh.17951

Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum (2021)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Taal, M. W., Aithal, G. P., Zhang, W., …Abhishek, A. (2022). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. Rheumatology, 61(7), 2783-2791. https://doi.org/10.1093/rheumatology/keab790

OBJECTIVE: To develop and validate a prognostic model for LEF discontinuation with abnormal blood test results. METHODS: Data from the Clinical Practice Research Datalink Gold and Aurum were used for model development and external validation, respect... Read More about Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum.

A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial (2021)
Journal Article
Fox, C. P., Ali, A. S., McIlroy, G., Thust, S., Martinez-Calle, N., Jackson, A. E., …Cwynarski, K. (2021). A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. Blood Advances, 5(20), 4073-4082. https://doi.org/10.1182/bloodadvances.2021004779

Relapsed or refractory primary central nervous system lymphoma (rrPCNSL) confers a poor prognosis with no accepted standard of care. Very few prospective studies have been conducted in this patient group. This study was a multicenter phase 1/2 study... Read More about A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial.

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data (2021)
Journal Article
Halligan, S. J., Grainge, M. J., Martinez-Calle, N., Fox, C. P., & Bishton, M. J. (2022). Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data. British Journal of Haematology, 196(4), 932-938. https://doi.org/10.1111/bjh.17896

Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immuno-conjugate Brentuximab Vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results... Read More about Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data.

Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England (2021)
Journal Article
Hounsome, L., Eyre, T. A., Ireland, R., Hodson, A., Walewska, R., Ardeshna, K., …Fields, P. A. (2022). Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England. British Journal of Cancer, 126(1), 134-143. https://doi.org/10.1038/s41416-021-01525-4

Background: We wished to examine treatment and outcome patterns in older diffuse large B-cell lymphoma (DLBCL) patients, with a focus on the effect of route-to-diagnosis to outcome. Methods: Data were extracted from Public Health England’s National C... Read More about Diffuse large B cell lymphoma (DLBCL) in patients older than 65 years: analysis of 3 year Real World data of practice patterns and outcomes in England.